Screener
Spyre Therapeutics, Inc. SYRE Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from maturities and sales of marketable securities | 107,748 | 71,383 |
| Purchases of marketable securities | (81,167) | (71,444) |
| Proceeds from sale of in-process research and development asset | 30,000 | — |
| Net cash provided by (used in) investing activities | 56,581 | (61) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs | 9,750 | — |
| Payment of deferred offering costs in connection with shelf registration | (171) | (93) |
| Proceeds from employee stock option exercises and employee stock plan purchases | 2,676 | 218 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s investing cash flow?
- Spyre Therapeutics, Inc. (SYRE) reported investing cash flow of $56.58M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Spyre Therapeutics, Inc.'s investing cash flow increased by 92855.7% year-over-year, from -$61K to $56.58M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s investing cash flow?
- Over 2 years (2022 to 2025), Spyre Therapeutics, Inc.'s investing cash flow has grown at a 58.6% compound annual growth rate (CAGR), from $57.01M to -$143.48M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Spyre Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude